ImmunoGen Company Profile (NASDAQ:IMGN)

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

ImmunoGen, Inc. (NASDAQ:IMGN) announced its quarterly earnings results on Friday, July, 28th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.07. The business earned $39.02 million during the quarter, compared to analysts' expectations of $30.59 million. ImmunoGen's revenue for the quarter was up 426.6% on a year-over-year basis. During the same period in the previous year, the company posted ($0.53) EPS. View ImmunoGen's Earnings History.

8 brokers have issued 1 year price objectives for ImmunoGen's shares. Their forecasts range from $1.30 to $12.00. On average, they anticipate ImmunoGen's share price to reach $7.72 in the next year. View Analyst Ratings for ImmunoGen.

Here are some recent quotes from research analysts about ImmunoGen stock:

• 1. According to Zacks Investment Research, "ImmunoGen has made significant progress with regard to its lead pipeline candidate, mirvetuximab soravtansine (platinum-resistant ovarian cancer). However, most of the pipeline candidates are in early stages of development and still a long way from entering the market, if at all. Moreover, ImmunoGen has only a limited number of wholly owned candidates in its pipeline. Hence successful development and subsequent approval of its lead candidate, is crucial for growth at ImmunoGen. On the flip side, the company’s collaborations with big healthcare companies not only validate its technology but also provide it with funds in the form of milestone and royalty payments. The company’s shares have outperformed the broader industry so far this year. Notably, estimates have been going down lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters." (7/10/2017)
• 2. Cantor Fitzgerald analysts commented, "IMGN’s announced sale of IMGN529 to Debiopharm for an aggregate of $55 mln provides incremental cash to the company for development of." (5/24/2017)
• 3. Cowen and Company analysts commented, "IMGN presented data from mrive’s Phase I biopsy expansion cohort at SGO." (3/13/2017)

Some companies that are related to ImmunoGen include Genomic Health (GHDX), Albany Molecular Research (AMRI), Biohaven Pharmaceutical Holding Co Ltd (BHVN), BeyondSpring (BYSI), Immunomedics (IMMU), Editas Medicine (EDIT), Heron Therapeutics (HRTX), Arena Pharmaceuticals (ARNA), Spectrum Pharmaceuticals (SPPI), Cellectis S.A. (CLLS), TG Therapeutics (TGTX), CRISPR THERAPTC (CRSP), Enanta Pharmaceuticals (ENTA), Mesoblast Limited (MESO), Intellia Therapeutics (NTLA), Kala Pharmctls (KALA), ANI Pharmaceuticals (ANIP) and Inovio Pharmaceuticals (INO).

ImmunoGen's management team includes the folowing people:

• Stephen C. McCluski, Independent Chairman of the Board
• Mark J. Enyedy, President, Chief Executive Officer, Director
• David B. Johnston PhD, Chief Financial Officer, Executive Vice President
• Ellie Harrison, Chief Human Resource Officer, Vice President
• Richard J. Gregory Ph.D., Executive Vice President - Research, Chief Scientific Officer
• John M. Lambert Ph.D., Executive Vice President - Distinguished Research Fellow
• Craig Barrows, Vice President, General Counsel, Secretary
• Peter J. Williams, Vice President - Business Development
• Mark A. Goldberg M.D., Independent Director
• Dean Jonathan Mitchell, Independent Director

ImmunoGen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (6.43%), Redmile Group LLC (5.82%), POLYGON MANAGEMENT LTD. (5.20%), Vanguard Group Inc. (4.87%), State Street Corp (4.62%) and Wells Fargo & Company MN (1.81%). Company insiders that own ImmunoGen stock include Charles Q Morris, Craig Barrows, Daniel M Junius, David Brannon Johnston, Dean J Mitchell, John Lambert, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Institutional Ownership Trends for ImmunoGen.

ImmunoGen's stock was sold by a variety of institutional investors in the last quarter, including KBC Group NV, Pinnacle Associates Ltd., Wells Fargo & Company MN, Teachers Advisors LLC, Creative Planning, Swiss National Bank, UBS Asset Management Americas Inc. and Northern Trust Corp. View Insider Buying and Selling for ImmunoGen.

ImmunoGen's stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, State Street Corp, Redmile Group LLC, EAM Investors LLC, Candriam Luxembourg S.C.A., Farallon Capital Management LLC, AXA and Fernwood Investment Management LLC. Company insiders that have bought ImmunoGen stock in the last two years include Craig Barrows, Dean J Mitchell, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Insider Buying and Selling for ImmunoGen.

Shares of ImmunoGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ImmunoGen stock can currently be purchased for approximately $6.07.